starting dose for cagrilintide Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise weight loss in early trials. The potential benefit Cagrilintide and Retatrutide for Men:

Phase 2 and Phase 3 trial data Major clinical trials: Phase 2 (24-week trial, 2008): 203 obese participants Three dose groups: 0.25mg, 0.5mg, 1.0mg daily Placebo-controlled, randomized Primary outcome: Weight loss percentage Phase 2 results: Key findings: Dose-dependent weight loss 1mg dose: Average 23 lbs lost (starting weight ~220 lbs) Best responders: 15-20% weight loss Comparable to semaglutide 2.4mg But higher dropout due to side effects Phase 3 trials (planned but never completed): Intended for FDA approval Halted due to cardiovascular concerns Increased heart rate 5-10 bpm average Blood pressure elevation 2-5 mmHg Risk-benefit ratio questioned Development suspended 2010 Long-term data (limited): 1-year extension studies showed sustained loss Weight plateau at 6-9 months Some regain if discontinued No controlled trials beyond 1 year Safety concerns prevented longer studies Compare to semaglutide trials and tirzepatide results

Modifying the Microbiome Its believed that the microflora of the digestive tract (the microbiome) play a significant role in IBD in cats

How fast

Korolchuk, S

Insulin resistance improvements were documented using the homeostatic model assessment of insulin resistance (HOMA-IR), which decreased by an average of 15% during resistant starch supplementation

METHODS All animal procedures were approved by the Institutional Animal Care and Use Committee of the Pusan National University Hospital (approval number: PNUH-2019-157)